PRESS RELEASE published on 03/30/2026 at 08:30, 2 months 2 days ago NANOBIOTIX Announces Presentation of First Data from a Randomized Phase 2 Clinical Trial Evaluating JNJ-1900 (NBTXR3) in Stage 3 Inoperable Lung Cancer NANOBIOTIX announces first data from phase 2 trial on JNJ-1900 for stage 3 lung cancer presented by Johnson & Johnson at European Lung Cancer Conference Phase 2 Trial NANOBIOTIX Lung Cancer Johnson & Johnson JNJ-1900
BRIEF published on 03/26/2026 at 21:20, 2 months 6 days ago Nanobiotix Announces the Publication of its 2025 Annual Results Financial Results Biotechnology NANOBIOTIX Online Conference Nanoparticles
BRIEF published on 03/26/2026 at 21:20, 2 months 6 days ago NANOBIOTIX to Release 2025 Financial Results and Update Conference Call Biotechnology Market Update 2025 Financial Results Nanoparticle Treatments
PRESS RELEASE published on 03/26/2026 at 21:15, 2 months 6 days ago NANOBIOTIX to Announce Fourth Quarter and Full Year 2025 Operational and Financial Update on March 31st, 2026 Nanobiotix to announce fourth quarter and full year 2025 operational and financial update on March 31, 2026. Conference call and webcast scheduled for April 1, 2026 Conference Call Webcast Financial Update NANOBIOTIX Late-clinical Stage Biotechnology
BRIEF published on 03/25/2026 at 15:16, 2 months 7 days ago NANOBIOTIX denies takeover rumors Biotechnology Takeover NANOBIOTIX Rumors Nanoparticles
BRIEF published on 03/25/2026 at 15:16, 2 months 7 days ago NANOBIOTIX Responds to Media Speculation on Takeover Intentions Biotechnology Nanotechnology Takeover Speculation NANOBIOTIX Public Statement
PRESS RELEASE published on 03/25/2026 at 15:11, 2 months 7 days ago NANOBIOTIX Statement Regarding Recent Media Speculation Nanobiotix issues statement addressing media speculation on public take-over intentions, denying any such plans and highlighting factual inaccuracies in recent reports Media Speculation Statement NANOBIOTIX Public Take-over Factual Inaccuracies
BRIEF published on 03/12/2026 at 21:20, 2 months 20 days ago Nanobiotix Announces Voting Rights and Share Capital Details Euronext Paris Share Capital Voting Rights Nasdaq NANOBIOTIX
PRESS RELEASE published on 03/12/2026 at 21:15, 2 months 20 days ago Voting Rights and Shares Capital of the Company Nanobiotix discloses voting rights and shares capital details as of February 28, 2026, on Euronext Paris and Nasdaq markets. Learn about their disruptive therapeutic approaches and global presence Euronext Paris Voting Rights Nasdaq Shares Capital NANOBIOTIX
BRIEF published on 02/25/2026 at 22:20, 3 months 4 days ago NANOBIOTIX Presents at Key Conferences in March Biotechnology Investor Conferences Cancer Treatments NANOBIOTIX Clinical Advances
Published on 06/01/2026 at 23:57, 2 hours 51 minutes ago Metallic Minerals Announces Bought Deal LIFE Private Placement for Gross Proceeds of C$8.0 Million
Published on 06/01/2026 at 23:05, 3 hours 43 minutes ago Faraday Copper Strengthens Team to Support Project Advancement in Arizona
Published on 06/01/2026 at 23:00, 3 hours 48 minutes ago CCL Industries Closing of Sleever International Acquisition
Published on 06/01/2026 at 22:30, 4 hours 18 minutes ago Revolve to Present at the Small Cap Growth Virtual Investor Conference on June 4, 2026
Published on 06/02/2026 at 02:15, 33 minutes ago At COMPUTEX 2026, YPlasma Unveils the First Fanless Solid-State Cooling for NVIDIA Jetson
Published on 06/02/2026 at 01:50, 58 minutes ago Mesabi Metallics Monetizes Portion of Royalty Interest for $265 Million
Published on 06/01/2026 at 23:00, 3 hours 48 minutes ago DriveNets Secures $410M Series D to Meet Surging Demand for Ethernet Fabric in Large-Scale AI Deployments
Published on 06/01/2026 at 22:05, 4 hours 43 minutes ago EUROPEAN COMMISSION APPROVES AMGEN'S IMDYLLTRA® FOR THE TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG CANCER
Published on 06/01/2026 at 22:05, 4 hours 43 minutes ago Abivax Announces Landmark Phase 3 ABTECT Maintenance Trial Results Evaluating Obefazimod in Moderately to Severely Active Ulcerative Colitis
Published on 06/01/2026 at 18:47, 8 hours 1 minute ago Disclosure of transactions in own shares from May 25 to May 29, 2026
Published on 06/01/2026 at 18:00, 8 hours 48 minutes ago Covivio - Information on total number of voting rights and share capital
Published on 06/01/2026 at 17:54, 8 hours 54 minutes ago Reporting on share buyback transactions carried out on May 28, 2026
Published on 06/01/2026 at 17:54, 8 hours 54 minutes ago TF1 - Monthly disclosure of the total number of shares and voting rights - May 2026
Published on 06/01/2026 at 17:45, 9 hours 3 minutes ago ENGIE secures €1 billion export financing backed by Euler Hermes
